Moderna Soars over 5% on Positive Cancer Therapy Results and Analyst Upgrade
Tiger Newspress01-22 17:52
Moderna saw its stock price soar 5.12% in pre-market trading, continuing its strong momentum from the previous session. The surge is driven by positive clinical trial results for Moderna's experimental skin cancer vaccine developed in collaboration with Merck & Co. The Phase 2b study showed that adding Moderna's intismeran autogene to KEYTRUDA significantly reduced the risk of recurrence or death in melanoma patients, with sustained benefits over five years.
Additionally, Bernstein raised Moderna's target price to $35 from $25, reflecting increased confidence in the company's growth trajectory. These developments have fueled investor optimism, leading to the stock's pre-market rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
